Sytrinol's Health BenefitsLower Total, LDL "bad cholesterol" & Triglycerides
The cardio-protective and cholesterol-lowering claims for Sytrinol™ are supported by human trials. Two early trials, consisting of ten subjects each, measured the effects of Sytrinol in men and women diagnosed with hypercholesterolemia (elevated cholesterol) and screened to eliminate thyroid disorders, kidney disorders and diabetes. Subjects were instructed to maintain normal dietary habits and discontinue using vitamins, supplements and cholesterol-lowering medications for at least 6 weeks prior to, and during the study. Fasting blood samples were drawn at the onset and end of each 4-week trial, and plasma lipids profiles and other metabolic parameters were analyzed using standard methods.
The results from the first trial show that four weeks of treatment with Sytrinol (300 mg/day) caused significant reductions in: total cholesterol (-24%); LDL cholesterol (-19%); and triglycerides (-23%). There were no changes in HDL cholesterol levels, and body mass remained relatively stable.
In the second trial, subjects with elevated cholesterol again benefited from only four weeks of treatment with Sytrinol (300 mg/day). Treatment with Sytrinol caused significant reductions in: plasma total cholesterol (19.7%); LDL cholesterol (22.01%); apo B (20.9%); and triglycerides (28.4%). Additionally, subjects in the second trial benefited from a significant 5% increase in apo-A1, an important structural protein of HDL
Compared to placebo, total cholesterol was reduced 30%, LDL cholesterol was reduced 27% and total triglycerides dropped 33%. Additionally, HDL cholesterol levels increased by 4%, resulting in a significant reduction in the LDL/HDL ratio of 30%.
- A study published in the May 12, 2005 issue of the Journal of Agricultural and Food Chemistry showed that PMFs reduced cholesterol by 24.7 per cent.
- They can lower triglycerides by as much as 28 per cent by decreasing levels of diacylglycerol acetyl transferase, the liver enzyme needed to produce them. High triglycerides are directly linked to heart attacks and heart disease because they contribute to the formation of plaque in the arteries.
- Studies also show that PMFs can decrease apolipoprotein B, the specific protein your liver needs to create LDL cholesterol. This has resulted in a 23-per cent drop in LDL cholesterol.
- The anti-inflammatory action of PMFs has been documented for over 38 years – well before doctors even realized that inflammation is a key cause of heart disease. Recent research shows that they can lower an inflammatory marker known as C-reactive protein (CRP). High levels of CRP can put you in the danger zone, since this protein substance is tied more directly to heart-attack risk than any other factor.
As powerful as PMFs are on their own, they're even more effective at lowering bad cholesterol when they're used in combination with tocotrienols. Tocotrienols are a form of vitamin E found in palms, rice bran, and barley that have been shown to reduce LDL cholesterol by lowering the activity of HMGR.
So scientists combined these two powerful ingredients, PMFs and tocotrienols, into the patented formula called Sytrinol. The researchers who developed Sytrinol also tested it in vitro, in vivo, and most importantly on hundreds of human subjects, using the same scientific protocols used by drug companies.
Tocotrienols and cardiovascular disease
One of the most striking discoveries in tocotrienol research is their ability to clear atherosclerotic blockage (stenosis) in the carotid artery, giving them the potential to significantly reduce the risk of stroke. Stroke often occurs when atherosclerotic deposits travel upstream and cut off the blood supply to part of the brain.
Tocotrienols show promise as a natural and safe alternative to risky surgery for this condition because of their ability to reverse carotid stenosis, not merely stop its progression. This was demonstrated in a clinical trial testing the effect of tocotrienols on carotid atherosclerosis. The results of this 18-month trial were remarkable.
Fifty patients with carotid stenosis were randomly assigned to receive either 160 mg daily of palm tocotrienols (gamma and alpha forms) with 64 mg of alpha-tocopherol in palm oil, or palm oil only as a placebo. After 6 months the dosage in the treatment group was increased to 240 mg of tocotrienols with 96 mg of alpha-tocopherol.
At the end of the study, ultrasound scans of the carotid artery demonstrated that none of the patients in the control group had improved during the trial, while ten showed a worsening of their condition (increased stenosis). In the tocotrienol group, however, atherosclerosis was reduced and blood flow to the brain improved in 7 of 25 patients, while the condition had worsened in only two patients. No adverse side effects were reported in either group.
Tocotrienols and statin drugs such as lovastatin both lower cholesterol by suppressing the activity of the enzyme HMG-CoA reductase, although through different mechanisms. The statins are thought to affect the enzyme through competitive inhibition, while the tocotrienols accelerate enzyme degradation and decrease the efficiency of mRNA translation of the enzyme. This difference in mechanism is believed to be a reason for the absence of adverse side effects with tocotrienols, contrary to the common side effects of the statin drugs.
Some studies have demonstrated a significant reduction of both total and LDL cholesterol with tocotrienols administered to patients with high serum lipids. In a double blind, crossover study on 25 patients with high cholesterol levels, the patients in the treatment group were given 4 capsules daily of 50 mg tocotrienols mixed with palm oil, while the control group received only corn oil. At the end of the 8-week trial period, total cholesterol and LDL cholesterol had decreased significantly (15% and 8%) in the 15 subjects given the palm tocotrienols. There was no change in the control group.
Total cholesterol and LDL-cholesterol were reduced even more (17 % and 24 % respectively) when tocotrienols were added to a low fat, low cholesterol diet and alcohol-free regimen in another double-blind, longer-lasting trial (12 weeks).
Other important cardiovascular risk factors were reduced by tocotrienols. Apoli-poprotein B and lipoprotein(a), strong predictors of cardiovascular disease, as well as thromboxane B2 and platelet factor 4 were all significantly lowered in the tocotrienol-treated group (15%, 17%, 31% and 14% respectively).
Tocotrienols were studied in combination with the statin drug lovastatin in another study. The 28 patients with elevated cholesterol levels in this double blind, cross-over clinical trial were placed on the American Heart Association Step-1 diet before beginning the treatment. After 35 days on the diet, they were given low doses of lovastatin, tocotrienols and alpha-tocopherol (and combinations of these agents) in stages of 35 days each, while staying on the diet. The combination of lovastatin (10mg) and palm tocotrienols (50mg) had a lipid-lowering effect of 20-25%, while tocotrienols or lovastatin alone in the same dosages reduced LDL-cholesterol 18% and 15% respectively. No side effects were reported during the study. It is important to note that dosages of cholesterol-lowering drugs should not be reduced on the basis of this preliminary study.
Help support healthy insulin sensitivity
Citrus peel compounds that are known as polymethoxylated flavones may help support healthy insulin sensitivity, according to a recent study.
While citrus peel extract has been reported to improve cholesterol levels, this study was the first to examine its effects on insulin sensitivity. Scientists fed hamsters a sugar-rich diet for two weeks to induce insulin resistance and elevated triglycerides. The insulin-resistant animals then received either a low or high dose of the citrus flavones tangeretin and nobiletin. Supplementing with citrus flavones for four weeks helped reverse impaired insulin sensitivity.
Since insulin resistance, diabetes, and obesity are considered inflammatory disorders, the researchers also measured levels of two biomarkers of inflammation, tumor necrosis factor-alpha and interleukin-6. Levels of these biomarkers decreased in both groups receiving citrus flavones, as did serum levels of triglycerides and cholesterol .
These results indicate that citrus peel extracts may help fight insulin resistance and diabetes, as well as support healthy blood lipid levels.
Anti-inflammatory agent for rheumatoid and osteo arthritis
In particular, the flavonoid nobiletin has been identified as a novel anti-inflammatory agent that has the potential to inhibit the degradation of articular cartilage in osteoarthritis and rheumatoid arthritis. Nobiletin has also been found to interfere with numerous inflammatory cytokines, including interleukin-1 beta and interleukin-6. These anti-inflammatory effects are comparable to those seen with powerful anti-inflammatory steroids such as dexamethasone. Tangeretin , another citrus flavonoid, has been found to offer complementary effects agai